Zhiyong Yang
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$13.4MFederal grants as PI19 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
19 awards · $13.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | SBIR Phase II Gut-Targeted IL-10 Delivery via Engineered Saccharomyces boulardii to Prevent Immune Checkpoint Inhibitor Colitis | $372K | FZATA INC |
| Sep 11, 2026 | NIH | SBIR Phase II Development of a Dual-Action Oral Immunotherapy for Clostridioides difficile Prevention | $313K | FZATA INC |
| Aug 10, 2023 | NIH | SBIR Phase II A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II) | $923K | FZATA INC |
| Apr 14, 2023 | NIH | SBIR Phase II Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track) | $951K | FZATA INC |
| Oct 24, 2022 | NIH | SBIR Phase II A Yeast-based Immunotherapy against Clostridioides difficile infection | $907K | FZATA INC |
| Aug 11, 2022 | NIH | SBIR Phase II A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II) | $988K | FZATA INC |
| May 1, 2022 | NIH | SBIR Phase II Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track) | $1.8M | FZATA INC |
| Apr 15, 2022 | NIH | SBIR Phase II Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track) | $855K | FZATA INC |
| Nov 5, 2021 | NIH | SBIR Phase II A Yeast-based Immunotherapy against Clostridioides difficile infection | $933K | FZATA INC |
| Jul 30, 2021 | NIH | SBIR Phase II A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II) | $1000K | FZATA INC |
| Apr 27, 2021 | NIH | SBIR Phase II Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track) | $252K | FZATA INC |
| Apr 1, 2021 | NIH | SBIR Phase II A Yeast-based Immunotherapy against Clostridioides difficile infection | $2.4M | FZATA INC |
| Mar 30, 2021 | NIH | SBIR Phase II A Yeast-based Immunotherapy against Clostridioides difficile infection | $554K | FZATA INC |
| Jul 20, 2020 | NIH | SBIR Phase II A Yeast-based Immunotherapy against Clostridioides difficile infection | $169K | FZATA INC |
| Jan 20, 2018 | NIH | SBIR Phase I A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection | $169K | FZATA INC |
| Jan 20, 2018 | NIH | SBIR Phase I A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection | $169K | FZATA INC |
| Jan 15, 2018 | NIH | SBIR Phase I Novel Immunotherapies for Comorbidity of Clostridium difficile and Inflammatory Bowel Disease | $225K | FZATA INC |
| Jan 5, 2018 | NIH | SBIR Phase I Novel Immunotherapies for Comorbidity of Clostridium difficile and Inflammatory Bowel Disease | $225K | FZATA INC |
| Dec 23, 2016 | NIH | SBIR Phase I A Yeast based Immunotherapy against Clostridium difficile Infection | $225K | FZATA INC |
1 patents as inventor
- US FZATA INC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#30
Awards as PI#21
Patents#273
Companies
- FZATA INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.